EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Gut Microbiome-Based Therapeutics in Critically Ill Adult Patients—A Narrative Review

Shiyue He, Fengyu Lin, Xinyue Hu, Pinhua Pan iD

Nutrients · 2023

DOI: 10.3390/nu15224734 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Nutrients, 2023. Verfasst von Shiyue He und 3 weiteren Autor:innen. Beteiligte Einrichtung: Center of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha 410008, China. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Microbiota. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 175 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The national key clinical specialist construction programs of China, Scientific Research Program of FuRong Laboratory, national key clinical specialist construction programs of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The gut microbiota plays a crucial role in the human microenvironment. Dysbiosis of the gut microbiota is a common pathophysiological phenomenon in critically ill patients. Therefore, utilizing intestinal microbiota to prevent complications and improve the prognosis of critically ill patients is a possible therapeutic direction. The gut microbiome-based therapeutics approach focuses on improving intestinal microbiota homeostasis by modulating its diversity, or treating critical illness by altering the metabolites of intestinal microbiota. There is growing evidence that fecal microbiota transplantation (FMT), selective digestive decontamination (SDD), and microbiota-derived therapies are all effective treatments for critical illness. However, different treatments are appropriate for different conditions, and more evidence is needed to support the selection of optimal gut microbiota-related treatments for different diseases. This narrative review summarizes the curative effects and limitations of microbiome-based therapeutics in different critically ill adult patients, aiming to provide possible directions for gut microbiome-based therapeutics for critically ill patients such as ventilator-associated pneumonia, sepsis, acute respiratory distress syndrome, and COVID-19, etc.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal MicrobiomeMicrobiotaHumansAdultCritical IllnessFecal Microbiota TransplantationPrognosisDysbiosis

Stichwörter der Autor:innen

critically ill patientsfecal microbiota transplantationgut microbiome-based therapeuticsgut microbiotashort-chain fatty acid

Autor:innen und Institutionen

  • Center of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha 410008, China.
  • FuRong Laboratory, Changsha 410078, China.
  • National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha 410008, China.
  • Hunan Engineering Research Center for Intelligent Diagnosis and Treatment of Respiratory Disease, Changsha 410008, China.

ORCID-Profile: Pinhua Pan

Förderung

  • The national key clinical specialist construction programs of China
  • Scientific Research Program of FuRong Laboratory
  • national key clinical specialist construction programs of China
  • National Natural Science Foundation of China
  • Natural Science Foundation of ChangSha
  • Natural Science Foundation of Hunan Province of China

Zitieren

APA

He, S., Lin, F., Hu, X., & Pan, P. (2023). Gut Microbiome-Based Therapeutics in Critically Ill Adult Patients—A Narrative Review. Nutrients. https://doi.org/10.3390/nu15224734

Vancouver

He S, Lin F, Hu X, Pan P. Gut Microbiome-Based Therapeutics in Critically Ill Adult Patients—A Narrative Review. Nutrients. 2023. doi:10.3390/nu15224734

BibTeX
@article{He2023,
  author = {He, Shiyue and Lin, Fengyu and Hu, Xinyue and Pan, Pinhua},
  title = {Gut Microbiome-Based Therapeutics in Critically Ill Adult Patients—A Narrative Review},
  journal = {Nutrients},
  year = {2023},
  doi = {10.3390/nu15224734}
}
Kostenlos starten →